Summary The development of familial and sporadic breast cancer is based on genetic alterations of tumoursuppressor genes, for which loss of heterozygosity (LOH) is one mechanism of gene inactivation. 
Cytogenetic and molecular genetic analysis of breast cancer samples suggest that the development of human breast cancer is based on the accumulation of various genetic alterations, including activation of oncogenes as well as inactivation of tumour-suppressor genes (Black, 1994; El-Ashry and Lippmann, 1994) . Loss of normal tumour-suppressor protein function can occur through sequential gene mutation events (somatic alteration) or through a single mutational event of a remaining normal copy when a germline mutation is present. In inherited cancer this second event uncovers the constitutional recessive mutation. The second event is usually chromosome loss, mitotic recombination or partial chromosome deletion. A hallmark of the involvement of a tumour suppressor-gene in cancer development may be allelic loss in tumour DNA. Loss of heterozygosity (LOH) has been observed for several loci (lq, lp, 3p, 6q, 7q, lip, llq, 13q, 16q, 17p , and 17q) in familial and sporadic breast cancer with frequencies ranging between approximately 20% and 79% (Sato et al., 1990; Andersen et al., 1992; Chen et al., 1992; Futreal et al., 1992; Kirchweger et al., 1994; Wooster et al., 1994; Collins et al., 1995) .
Assessment of allelic loss of tumour-suppressor genes has been limited by the position and frequency of heterozygosity in instances where classical restriction length polymorphisms (RFLPs) are used. Because of their abundance, polymorphic nature and amenability to amplification by polymerase chain reaction (PCR), short tandem repeats (STRs) are much better markers for genomic mapping and genetic linkage analysis. STRs provide a source of highly informative loci for use in identification of individual allele patterns. The ability to resolve PCR products differing in size by just one base on polyacrylamide gels allows precise allele designation, even though enzyme slippage during amplification may result in artificial stutter bands. Thus, the ability to amplify multiple loci using different fluorescent primers in a single reaction coupled with direct detection of the fluorescent-labelled, amplified products on polyacrylamide gels makes STR DNA profiling amenable to automated fluorescent DNA technology.
Lately, two genes, BRCAJ, located on chromosome 17q21 (Hall et al., 1992; Easton et al., 1993; Miki et al., 1994; Futreal et al., 1994) and BRCA2, located on 13qI2- 13 (Wooster et al., 1995) , having been shown to be involved in familial breast and ovarian cancer. A third gene, the ataxia telangiectasia (AT) gene, may also contribute significantly to the development of hereditary breast cancer. Heterozygous carriers of the mutated gene (ATM) are at significantly increased risk owing to altered response to DNA damage and increased radiation sensitivity. However, ATM study data are still rare (Savitsky et al., 1995) . To date, in familial breast cancer, BRCAI mutations account for 45% and BRCA2 mutations for 40% of cases; in familial breast/ovarian cancer families BRCAJ mutations account for 80% of cases. Analysis of these BRCAI families has revealed individual risks of >90% and 44% of developing breast and ovarian cancer by the age of 80 respectively (Easton et al., 1993; Ford et al., 1994) . Concerning the BRCAJ gene, 80 mutations have been described Shattuck-Eidens et al., 1995) using single-strand conformation polymorphism (SSCP) analysis on PCR-amplified genomic DNA or direct sequencing. The heterogeneity of mutations, coupled with the large size of the gene, indicate that routine clinical application of BRCAJ mutation testing is technically challenging (Boyd, 1995; Hogervorst et al., 1995; ShattuckEidens et al., 1995 In preliminary experiments, the quality of DNA extracted from haematoxylin-eosin-stained sections was checked and compared with toluidine staining, another staining method frequently used. There was no difference in PCR results between both staining methods. Sections from routine pathological staining can therefore be used for molecular genetic analysis. Results were correlated with menopausal status, tumour size, number of lymph node metastases, histologic grading and ER or PgR expression.
DNA extraction
Genomic DNA from peripheral blood leucocytes was prepared by a standard protocol (Ausubel et al., 1994) .
Briefly, pellets of white blood cells were dispersed in Tris-HCl buffer (100 mM, pH 7.5) containing 0.5% sodium dodecyl sulphate (SDS) and digested with proteinase K (100 Mg ml-1) for 3 h at 45°C. After repeated extractions (phenolchloroform-isoamylalcohol, 25:24:1) high molecular weight genomic DNA was precipitated with salt-ethanol at -20°C for 2 h and dissolved in double-distilled water. Tumour DNA was extracted from tissue samples adjacent to a haematoxylin-eosin-stained section (5 gm) assessed for pathological diagnosis and tumour content (Shibata, 1994) . Frozen tissue samples were pulverised using a microdismembrator (Braun Melsungen, Germany) and dispersed in proteinase K digestion buffer (100 mM Tris-HCl pH 8.5, 1 mM EDTA, 0.5% SDS) with 100 Mg ml-1 proteinase K (Boehringer, Mannheim, Germany). After incubation for 12-16 h at 50°C samples were heated at 95°C for 10 min to inactivate proteinase K. This was followed by two extractions with phenol-chloroform-isoamylalcohol (25:24:1) and one with chloroform -isoamylalcohol (24:1). After ethanol -salt precipitation at -20°C DNA was spun, dried and resuspended in ddH2O. DNA was quantitated on a lambdaBio spectrophotometer (Perkin Elmer, Uberlingen, Germany). The primers were purchased from PharmaciaBiotech (Freiburg, Germany). Primer sequences were: D17S855 (5'-
, and D 13S267 (5'-F-GGCCTGAAAGG-TATCCTC, 5'-TCCCACCATAAGCACAAG). One primer of each primer pair was fluorescein-labelled (F) at the 5'end, all primers were purified through NAP 10 columns and stored at -20°C.
PCR reaction and fluorescent labelling The target sequences were amplified by PCR in 50 Ml of 1 x Taq polymerase reaction buffer containing 40 PCR fragment analysis PCR amplification products were analysed on 6% polyacrylamide denaturing gels in 0.6 x TBE buffer in an automated laseractivated fluorescent DNA sequencer (ALF, Pharmacia Biotech). Diluted PCR reaction mixture (5 Ml) (1:20-1:80) was mixed with 5 Ml of stop solution (90% formamide, 10 mM EDTA, 0.3% bromophenol blue) containing a fluorescentlabelled fragment of defined size as internal loading control. The mix was denatured at 95°C for 5 min, cooled on ice, loaded into a well on the preheated gel (40°C), and run for 3-4 h at 30W 4mA. While the samples were undergoing electrophoresis, fluorescence was detected after laser activation. Data were collected automatically during electrophoresis and calculated using Fragment Manager (FM 1.1) software (Pharmacia Biotech), which yields quantitation of results in terms of peak size, height and area under the curve.
Assessment of allelic loss
In heterozygous individuals two alleles, i.e. two PCR products of different size, can be detected in normal DNA. The sizes of two alleles were assigned to the peaks of greatest height following smaller peaks, which were interpreted as polymerase artefacts, so-called stutter bands. Because PCR fragments of different sizes are amplified with different efficiencies, the ratio of allele peak areas was calculated by comparing matched normal and tumour DNA samples. Peak areas of the larger length alleles were divided by the peak areas of the shorter length allele. The ratio obtained in tumour DNA divided by the allele peaks ratio of matched normal DNA has a mathematical range of 0.00-1.00. Theoretically, a complete allele loss in tumour tissue results in a value of 0.00, retention of both alleles in both tissues in a ratio of 1.00 (Sato et al., 1990; Lubin et al., 1991 (Lynch et al., 1994) . In 1990 an autosomal dominant susceptibility gene for breast and ovarian cancer, BRCAI, was assigned to chromosome 17q21 by multipoint genetic linkage (Hall et al., 1990 Albertsen et al., 1994) and was later cloned and sequenced . Observations of LOH for polymorphic markers widely spaced along chromosome 17q (Futreal et al., 1992; Hall et al., 1992; Easton et al., 1993; Knyazev et al., 1993; Kirchweger et al., 1994; Lalle et al., 1994) Niederacher et al., 1996) . The combination of both methods offers several advantages compared with other staining methods and autoradiography:
(1) It is much faster than Southern blot or radioactive PCR. Separation and direct quantification of PCR products can be performed automatically and requires approximately 3 h without additional staining steps. This allows quantification of as many as 40 individual samples simultaneously and 2-3 gels per day to be run on a routine basis.
(2) Fluorescent-labelled primers and PCR products can be stored, as labelling for both primers and products is stable for several months at -20°C.
(3) The enhanced sensitivity of the fluorescent detection method required 25-30 PCR cycles only to achieve detectable results. Linearity of fluorescence detection covers a much wider range than scanning of autoradiograms or ethidium bromide-or silver-stained gels, resulting in improved quality of data. Therefore, this approach is particularly suitable for the analysis of large series of samples and routine clinical use.
Various groups have analysed LOH at chromosomal region 17q close to the BRCAJ locus, for example, Futreal et al. (1992; THRAI, D17S579) , Knyazev et al. (1993; THH-59) , Cropp et al. (1993; 19 polymorphic markers) or Kirchweger et al. (1994; AFMl55xdl2, AFM234td2) , but very few studies used the intragenic markers D17S855 or D17S1323 Albertsen et al., 1994) . These studies did not intend primarily to use the detection of LOH for clinical purposes, but to focus on the localisation of potential breast cancer candidate genes. Therefore, the number of cases analysed were small (14-55) and correlations with clinical parameters were not extensive. In this study, we intended to obtain clinical information from the detection of LOH of BRCAI. For LOH of the BRCAJ region three different markers, one intragenic (D17S855) and two extragenic markers (THRAI, D17S579), were tested. In IDC, overall rates of LOH varied from 32% to 37% without significant differences between intragenic and extragenic markers. For ILC and other types of invasive breast carcinoma these rates extend from 21-28 to 41-43%. For ILC this revealed a difference between the intragenic D17S855 and the extragenic THRAI and D17S579 markers; for other types of invasive breast carcinoma the data were too few in number for statistical analysis. Other studies (Futreal et al., 1992; Knyazev et al., 1993; Kirchweger et al., 1994) have reported 29-79% of LOH, but no differences between tumour types have been stated. This should be taken into consideration when comparing LOH data from different studies. For example for IDC, our data are similar to those by the Kirchweger group, but the data for ILC vary significantly. This implies that: (1) the genetic basis of tumorigenesis varies between different types of breast tumours and (2) the use of a single extragenic marker to characterise LOH of a specific tumour-suppressor gene is not sufficient to obtain clinical information. In hereditary breast cancer (Jacquemier et al., 1995) (Kirchweger et al., 1994; Devilee and Cornelisse, 1994; Niederacher et al., 1996) . 
